LZB:NYSELa-Z-Boy Incorporated Analysis
Data as of 2026-06-17 - not real-time
$35.06
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
La‑Z‑Boy just reported a strong fiscal Q4, highlighted by retail sales growth. Margins improved, with operating margin climbing to 5.4% and profit margin to 3.9%. The company completed the sale of its American Drew and Kincaid wholesale case‑goods businesses, sharpening focus on higher‑margin upholstered lines. Revenue rose 3.8% year‑over‑year to $2.13 B. Forward EPS guidance of $3.29 translates to a forward PE near 10.7. Analysts have issued a “buy” rating with a median price target of $44.5. The stock opened at $37.99 and is now trading at $35.06, below the 20‑day SMA of $36.89 and the 50‑day SMA of $35.64. RSI sits at 42, indicating neutral momentum, while volume is trending upward. Market sentiment is in Extreme Greed (FGI 92), adding a behavioral boost.
Valuation models place fair value at $67.08, implying roughly 27% upside. The current 2.56% dividend yield with a 45% payout is backed by solid operating cash flow and $194 M free cash flow. A beta of 0.89 and 30‑day volatility of 38% suggest moderate price swings. Consumer‑cyclical exposure brings higher sector risk, but low price‑to‑book (1.38) and price‑to‑sales (0.68) signal an undervalued profile. The blend of value metrics and modest growth steers the thesis toward a value play. Investors should watch the upcoming earnings call for confirmation of margin trends and guidance. Overall, the stock offers a compelling risk‑adjusted upside for patient investors.
Valuation models place fair value at $67.08, implying roughly 27% upside. The current 2.56% dividend yield with a 45% payout is backed by solid operating cash flow and $194 M free cash flow. A beta of 0.89 and 30‑day volatility of 38% suggest moderate price swings. Consumer‑cyclical exposure brings higher sector risk, but low price‑to‑book (1.38) and price‑to‑sales (0.68) signal an undervalued profile. The blend of value metrics and modest growth steers the thesis toward a value play. Investors should watch the upcoming earnings call for confirmation of margin trends and guidance. Overall, the stock offers a compelling risk‑adjusted upside for patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Upcoming earnings volatility
- Bearish MACD histogram
- Price near support levels
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued DCF with ~27% upside
- Improving margins and dividend yield
- Analyst buy rating and target price
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable dividend and cash flow
- Strategic focus on higher‑margin segments
- Long‑term value metrics (low P/B, low P/S)
Key Metrics & Analysis
Financial Health
Revenue Growth3.80%
Profit Margin3.93%
P/E Ratio19.0
ROE8.09%
ROA4.31%
Debt/Equity53.88
P/B Ratio1.4
Op. Cash Flow$237.7M
Free Cash Flow$194.7M
Technical Analysis
TrendBullish
RSI42.2
Support$33.49
Resistance$39.30
MA 20$36.89
MA 50$35.64
MA 200$35.44
MACDBearish
VolumeIncreasing
Fear & Greed Index92.13
Valuation
Fair Value$67.08
Target Price$44.50
Upside/Downside26.93%
GradeUndervalued
TypeValue
Dividend Yield2.56%
Risk Assessment
Beta0.89
Volatility37.82%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.